

Elfabrio® (pegunigalsidase alfa-iwxj) **Medication Precertification Request**

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification Phone: <u>1-866-752-7021</u> (TTY: <u>711</u>)

FAX: 1-888-267-3277

For Medicare Advantage Part B: Please Use Medicare Request Form

Please indicate: Start of treatment, start date:		Continuation of the	nerapy, date of last	treatment: _	1 1		
Precertification Requested By:		Phone	:	Fax:			
A. PATIENT INFORMATION	_						
First Name:	Last Name:			DOB:			
Address:		City:		State:	ZIP:		
Home Phone: Work Phone:		Cell Phone:		E-mail:	•		
Current Weight: lbs or kgs Height: _	inches or cm	ns Allergies:					
B. INSURANCE INFORMATION							
Member ID #:	er coverage?	☐ Yes ☐ No					
Group #:	If yes, provide ID#:		_ Carrier Name:				
Insured:	Insured:	Insured:					
Medicare: ☐ Yes ☐ No If yes, provide ID #:		Medicaid: Yes	s ☐ No If yes, prov	vide ID #:			
C. PRESCRIBER INFORMATION							
First Name:	Last Name:	1	(Check one):	<u> </u>	0.O. N.P. P.A.		
Address:		City:	T.	State:	ZIP:		
Phone: Fax:	St Lic #:	NPI #:	DEA #:		UPIN:		
Provider E-mail:	Office Contact Name:			Phone:			
Specialty (Check one): Ophthalmologist Nephr	ologist 🗌 Other:						
D. DISPENSING PROVIDER/ADMINISTRATION INFOR	MATION						
Place of Administration:		Dispensing Provider/Pharmacy: (Patient selected choice)					
☐ Self-administered ☐ Physician's Office		☐ Physician's Office ☐ Retail Pharmacy					
Outpatient Infusion Center Phone: Center Name:							
Home Infusion Center Phone:		Name:					
Agency Name:							
Administration code(s) (CPT):		-		<u> </u>			
Address:		TIN:		PIN:			
E. PRODUCT INFORMATION		D					
Request is for: Fabrazyme (agalsidase beta) Dose							
F. DIAGNOSIS INFORMATION - Please indicate primary			here applicable (*).				
Primary ICD Code:		r ICD Code:					
G. CLINICAL INFORMATION - Required clinical informa For All Requests (clinical documentation required for	· · · · · · · · · · · · · · · · · · ·	or ALL precertification	on requests.				
☐ Yes ☐ No Is this infusion request in an outpatient hospital setting? ☐ Yes ☐ Yes ☐ No Has the patient experienced an adverse event with the requested product that has not responded to conventional							
interventions (e.g., acetaminophen, steroids, diphenhydramine, fluids, other pre-medications or slowing of infusion rate) or a severe adverse event (anaphylaxis, anaphylactoid reactions, myocardial infarction, thromboembolism, or seizures) during or							
severe adverse event (anaphylaxis, anaphylactoid reactions, myocardial infarction, thromboembolism, or seizures) during or immediately after an infusion?							
	Yes No Has the patient developed laboratory confirmed anti-pegunigalsidase alfa-iwxj IgG or IgE antibodies which increases the risk for infusion related reactions?						
☐ Yes ☐ No Does the patient have severe venous access issues that require the use of special interventions only available in the outpatient hospital setting?							
Yes No Does the patient have significant behavioral issues and/or physical or cognitive impairment that would impact the safety of the infusion therapy AND the patient does not have access to a caregiver?							
Please provide a des	•	•					
Yes No Is the patient medically unstable which may include respiratory, cardiovascular, or renal conditions that may limit the member's ability to tolerate a large volume or load or predispose the member to a severe adverse event that cannot be managed in an alternate setting without appropriate medical personnel and equipment?							
Please provide a description of the condition: Cardiopulmonary:							
Respiratory:							
	☐ Renal:						
		_ Other:					
☐ Yes ☐ No Does the patient have a diagnosis of Fall	ory disease?						



Elfabrio® (pegunigalsidase alfa-iwxj) Medication Precertification Request

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification Phone: <u>1-866-752-7021</u> (TTY: <u>711</u>)

1-888-267-3277

For Medicare Advantage Part B: Please Use Medicare Request Form

Patient First Na	me	Patient Last Name	Patient Phone	Patient DOB				
G. CLINICAL INFORMATION (continued) – Required clinical information must be completed in its entirety for all precertification requests.								
For Initiation Requests (clinical documentation required for all requests):								
 Yes ☐ No Will the requested medication be used concomitantly with Galafold (migalastat)? 								
For Continuation Requests (clinical documentation required for all requests):								
Yes No Is the patient responding to therapy (e.g., reduction in plasma globotriaosylceramide [GL-3, Gb3] or GL-3/Gb3 inclusions, improvement and/or stabilization in renal function, pain reduction)?								
H. ACKNOWLEDGEMENT								
Request Com	pleted By (Signature Requ	uired):		Date: /				
Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties.								

The plan may request additional information or clarification, if needed, to evaluate requests.